SCYNEXIS Acquires PXL-770 for $8M Upfront

SCYNEXIS, Inc. completed its acquisition of PXL-770 (now SCY-770) from Poxel S.A. SCY-770 is an oral, highly selective direct AMPK activator for autosomal dominant polycystic kidney disease (ADPKD).

Under the acquisition agreement, SCYNEXIS will make an upfront payment of $8 million, with future development milestones of up to $8 million and commercial milestones of up to $180 million. SCY-770 has been evaluated in eight clinical trials with a favorable safety profile and has FDA Orphan Drug Designation. SCYNEXIS expects to begin a Phase 2 proof-of-concept study in Q4 2026, with an early efficacy readout in the second half of 2027.